Drugs / Aminolevulinic Acid (ALA)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02281136 | Dec 2014 → Apr 2015 | actinic keratosis | DUSA Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 0 | NCT03114111 Comparator | Jan 2017 → Dec 2019 | seborrheic dermatitis | University of California, Davis | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aminolevulinic acid (ALA) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03114111 ↗ |
| Route | Topical | “when applied topically under occlusion” NCT02281136 ↗ |